Heartseed (219A) · InitiativeRestated
Remuscularization (myocardial replacement therapy)
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Myocardial Supplementation Therapy through RemuscularizationA theme 1 companies write about · 0 as a headwind · 3 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Our myocardial regeneration therapy is distinct from conventional cell therapies. It replaces a weakened heart with regenerated myocardium and is known as "Remuscularization (myocardial replacement therapy)."」
The Company continues to describe myocardial replacement therapy as its treatment approach, distinct from conventional cell therapies. - FY2024First statedAnnual report
「Our myocardial regeneration therapy is distinct from conventional cell therapies. It replaces a weakened heart with regenerated myocardium and is known as "Remuscularization (myocardial replacement therapy)."」
The Company describes its unique treatment concept of replacing weakened heart tissue with regenerated myocardium through the long-term engraftment of transplanted cells.